Major depressive disorder (MDD) clinical trials face some of the toughest challenges in neuroscience—high placebo response rates, data variability, and global enrollment hurdles. In this case study, see how a sponsor partnered with Premier Research for their phase 3 program to overcome these obstacles and deliver results that far exceeded industry norms.
By downloading, you’ll discover how the program:
- Achieved an effect size twice the typical benchmark in MDD studies
- Navigated geopolitical disruptions while maintaining global balance in enrollment
- Minimized patient and site burden with smarter operational strategies
- Leveraged innovative data review methods to ensure clean, conclusive outcomes
Get the full story
By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Premier Research that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.